Objectives: We sought to determine the prevalence of treatable left ventricular (LV) systolic dysfunction (LVSD) in patients who present with their first noncardiac vascular episode.

Background: Screening for LV dysfunction in patients who present with their first stroke (cerebrovascular accident), their first transient ischemic attack (TIA) or their first manifestation of peripheral vascular disease (PVD) may represent a golden opportunity to identify treatable LV dysfunction, and so their known high incidence of sudden cardiac death may be reduced.

Methods: Participating in this study were 522 (75%) of 700 consecutive patients (302 patients with stroke, TIA or PVD and 220 age- and gender-matched control subjects). Each underwent a full clinical assessment, 12-lead electrocardiography and two-dimensional echocardiography. Left ventricular dysfunction was defined as LV ejection fraction < or = 40%.

Results: Seventy-two (28%) patients with vascular disease and 11 (5.5%) control subjects were found to have LVSD. Twenty-six (28%) stroke patients, 22 (26%) patients with TIA and 24 (31%) patients with PVD had LVSD. Left ventricular systolic dysfunction was symptomatic in 44% of patients and in 35% of control subjects.

Conclusions: Left ventricular systolic dysfunction is five times more common among patients with stroke, TIA and PVD than among age- and gender-matched control subjects. Asymptomatic LVSD is more common than symptomatic LVSD in these patients. These findings suggest that routine screening of all patients with noncardiac vascular episodes for LVSD should now be considered. Future studies should investigate whether identifying and treating LVSD in these patients would reduce their known high rate of cardiac death.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0735-1097(01)01725-9DOI Listing

Publication Analysis

Top Keywords

left ventricular
20
ventricular systolic
16
systolic dysfunction
16
patients
14
patients noncardiac
12
noncardiac vascular
12
lvsd patients
12
patients stroke
12
control subjects
12
prevalence treatable
8

Similar Publications

The study was designed to investigate the pattern of intraventricular Hemo-Dynamic Forces (HDF) and myocardial performance during exercise in Elite Cyclists (EC). Transthoracic stress echocardiography was performed on nineteen EC and thirteen age-matched sedentary controls (SC) at three incremental exercise intensities based on Heart Rate Reserve (HRR). Left Ventricular (LV) HDF were computed from echocardiography long-axis data sets using a novel technique based on endocardial boundary tracking, both in apex-base and latero-septal directions.

View Article and Find Full Text PDF

The authors propose a modified transcatheter aortic valve replacement technique wherein the removal of the guidewire and delivery catheter immediately after the valve implantation helps to not only shorten the procedure but also decrease complications induced by the guidewire and delivery catheter.

View Article and Find Full Text PDF

Outcomes of a transapical edge-to-edge repair system in secondary mitral regurgitation.

J Invasive Cardiol

January 2025

Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University; NHC Key Laboratory of Ischemic Heart Diseases; Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences; National Clinical Research Center for Interventional Medicine, Shanghai, China.

Objectives: The ValveClamp system (Hanyu Medical Technology) is a novel transcatheter edge-to-edge repair (TEER) system designed for ease of operation; however, there is a lack of data on its application in secondary mitral regurgitation (SMR). The authors report the mid-term outcomes of TEER using the ValveClamp system in SMR.

Methods: The study prospectively analyzed consecutive severe SMR patients who underwent transapical ValveClamp implantation at 10 Chinese centers.

View Article and Find Full Text PDF

Blood Pressure Control and Incident Left-Ventricular Conduction Disease.

Curr Cardiol Rep

January 2025

Division of Cardiology, Department of Medicine, University of California San Francisco, 505 Parnassus Ave, M1180B, San Francisco, CA, 94143, USA.

Purpose Of Review: Cardiac conduction disease, a harbinger of pacemaker implantation, heart failure, and death, is commonly regarded as immutable. However, emerging research suggests it may be a target for upstream prevention strategies such as blood pressure management. This review summarizes recent evidence regarding blood pressure control and the development of conduction disease.

View Article and Find Full Text PDF

Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity.

Eur Heart J

January 2025

School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 2199 Lishui Rd, Nanshan, Shenzhen, Guangdong Province 518055, China.

Background And Aims: Lackluster results from recently completed gene therapy clinical trials of VEGF-A delivered by viral vectors have heightened the need to develop alternative delivery strategies. This study aims to demonstrate the pre-clinical efficacy and safety of extracellular vesicles (EVs) loaded with VEGF-A mRNA for the treatment of ischaemic vascular disease.

Methods: After encapsulation of full-length VEGF-A mRNA into fibroblast-derived EVs via cellular nanoporation (CNP), collected VEGF-A EVs were delivered into mouse models of ischaemic injury.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!